Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
The Wnt pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes. Abnormalities in the Wnt pathway have been linked to many human diseases, revealing a powerful underlying biology with relevance to a broad spectrum of organs and tissues. Surrozen is implementing a platform of `surrogate` Wnt molecules to selectively activate the Wnt pathway for the treatment of injury and disease—overcoming key hurdles that have held back ...
Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
The Wnt pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes. Abnormalities in the Wnt pathway have been linked to many human diseases, revealing a powerful underlying biology with relevance to a broad spectrum of organs and tissues. Surrozen is implementing a platform of `surrogate` Wnt molecules to selectively activate the Wnt pathway for the treatment of injury and disease—overcoming key hurdles that have held back industry-wide drug development efforts in this promising area of biology.
Surrozen is founded by four leading edge scientists from Stanford University: K. Christopher Garcia, Ph.D. Roel Nusse, Ph.D. Calvin Kuo, M.D., Ph.D.; and Claudia Janda, Ph.D. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen`s technology and approach to therapeutic development.
-
Number of Employees:
25-100
-
Annual Revenue:
$0-1 Million